Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

The relationship between neurodegenerative conditions and late-life mood disorders (LLMDs) is largely unexplored.

MSD has begun the randomised MOBILIZE-1 Phase III trial to assess the investigational quadrivalent vaccine, V181.

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in ...